The burden of chronic pain for patients with osteoarthritis in Germany: a retrospective cohort study of claims data

被引:5
作者
Schild, Marie [1 ]
Mueller, Ulrike [2 ]
von Schenck, Ursula [3 ]
Prieur, Sigurd [3 ]
Miller, Robert [1 ,2 ]
机构
[1] Pfizer Germany GmbH, Berlin, Germany
[2] Pfizer Pharma GmbH, Linkstr 10, D-10785 Berlin, Germany
[3] Elsevier Hlth Analyt, Berlin, Germany
关键词
Health insurance; Health care costs; Cost of illness; Direct service costs; Sick leave; KNEE OSTEOARTHRITIS; HIP; IMPACT; RECOMMENDATIONS; EPIDEMIOLOGY; MANAGEMENT;
D O I
10.1186/s12891-021-04180-1
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background Osteoarthritis (OA) is a common condition that is often associated with chronic pain. Pain often leads patients to seek healthcare advice and treatment. In this retrospective cohort analysis of German longitudinal healthcare claims data, we aimed to explore the healthcare resource utilisation (HRU) and related healthcare costs for patients with OA who develop chronic pain. Methods Patient-level data was extracted from the German Institut fur Angewandte Gesundheitsforschung (InGef) database. Insured persons (>= 18 years) were indexed between January 2015 and December 2017 with a recent (none in the last 2 years) diagnosis of OA. HRU and costs were compared between patients categorised as with (identified via diagnosis or opioid prescription) and without chronic pain. Unweighted HRU (outpatient physician contacts, hospitalisations, prescriptions for physical therapy or psychotherapy, and incapacity to work) and healthcare costs (medication, medical aid/remedy, psychotherapy, inpatient and outpatient and sick pay in Euros [quartile 1, quartile 3]) were calculated per patient for the year following index. Due to potential demographic and comorbidity differences between the groups, inverse probability of treatment weighting (IPTW) was used to estimate weighted costs and rate ratio (RR; 95% confidence interval) of HRU by negative binomial regression modelling. Results Of 4,932,543 individuals sampled, 238,306 patients with OA were included in the analysis: 80,055 (34%) categorised as having chronic pain (24,463 via opioid prescription) and 158,251 (66%) categorised as not having chronic pain. The chronic pain cohort was slightly older, more likely to be female, and had more comorbidities. During the year following index, unweighted and IPTW-weighted HRU risk and healthcare costs were higher in patients with chronic pain vs those without for all categories. This led to a substantially higher total annual healthcare cost observed mean; euro6801 (1439, 8153) vs euro3682 (791, 3787); estimated RR = 1.51 (1.36, 1.66). Conclusions German patients with chronic pain and OA have higher healthcare costs and HRU than those with OA alone. Our findings suggest the need for better prevention and treatment of OA in order to reduce the incidence of chronic pain, and the resultant increase in disease burden experienced by patients.
引用
收藏
页数:10
相关论文
共 30 条
[11]   American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee [J].
Hochberg, Marc C. ;
Altman, Roy D. ;
April, Karine Toupin ;
Benkhalti, Maria ;
Guyatt, Gordon ;
McGowan, Jessie ;
Towheed, Tanveer ;
Welch, Vivian ;
Wells, George ;
Tugwell, Peter .
ARTHRITIS CARE & RESEARCH, 2012, 64 (04) :465-474
[12]   The Burden of Pain Associated with Osteoarthritis in the Hip or Knee from the Patient's Perspective: A Multinational Cross-Sectional Study [J].
Jackson, James ;
Iyer, Ravi ;
Mellor, Jennifer ;
Wei, Wenhui .
ADVANCES IN THERAPY, 2020, 37 (09) :3985-3999
[13]  
Jacobs H, 2019, BUNDESGESUNDHEITSBLA, V62, P1013, DOI 10.1007/s00103-019-02986-y
[14]   Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries [J].
Kingsbury, Sarah R. ;
Gross, Hillary J. ;
Isherwood, Gina ;
Conaghan, Philip G. .
RHEUMATOLOGY, 2014, 53 (05) :937-947
[15]  
Kolasinski SL, 2020, ARTHRIT CARE RES, V72, P149, DOI [10.1002/acr.24131, 10.1002/art.41142]
[16]  
Lützner J, 2018, ORTHOPADE, V47, P777, DOI 10.1007/s00132-018-3612-x
[17]  
Matziolis G, 2019, S2K LEITL KOX REG 03
[18]   OARSI guidelines for the non-surgical management of knee osteoarthritis [J].
McAlindon, T. E. ;
Bannuru, R. R. ;
Sullivan, M. C. ;
Arden, N. K. ;
Berenbaum, F. ;
Bierma-Zeinstra, S. M. ;
Hawker, G. A. ;
Henrotin, Y. ;
Hunter, D. J. ;
Kawaguchi, H. ;
Kwoh, K. ;
Lohmander, S. ;
Rannou, F. ;
Roos, E. M. ;
Underwood, M. .
OSTEOARTHRITIS AND CARTILAGE, 2014, 22 (03) :363-388
[19]   The epidemiology and impact of pain in osteoarthritis [J].
Neogi, T. .
OSTEOARTHRITIS AND CARTILAGE, 2013, 21 (09) :1145-1153
[20]   Prevalence and treatment of hip and knee osteoarthritis in people aged 60 years or older in Germany: an analysis based on health insurance claims data [J].
Postler, Anne ;
Ramos, Andres Luque ;
Goronzy, Jens ;
Guenther, Klaus-Peter ;
Lange, Toni ;
Schmitt, Jochen ;
Zink, Angela ;
Hoffmann, Falk .
CLINICAL INTERVENTIONS IN AGING, 2018, 13 :2339-2349